Security key
52886N406
- Security type / class
- Equity / COM NEW
- Total 13F shares
- 1,490,596
- Total 13F value
- $1,166,763
- Share change
- -278,448
- SEC-reported price per share
- $0.78
- Number of holders
- 28
- Value change
- -$217,532
- Number of buys
- 9
- Number of sells
- 9
Report period
Q1 2026
Institutions
28
Top holders
10
LEXX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
Lexaria Bioscience Corp. SEC filings
Lexaria Bioscience Corp. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 52886N406
Recent filing periods:
Ownership snapshot
Top reported holders of LEXX - Lexaria Bioscience Corp. - COM NEW (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Christopher Bunka
Disclosed value leader
Christopher Bunka
Comparable rows
0/15
Latest evidence
17 Mar 2026
3/4/5
13F
Highest disclosed value: $533,006
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Christopher Bunka has the largest disclosed position value at $533K.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Christopher Bunka's linked filing trail.
Disclosed position value
Top 5
Christopher Bunka
$533K
Richard Christopher
$363.6K
John Martin Docherty
$322.5K
Invenomic Capital Management LP
$290.6K
UBS Group AG
$222.9K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Christopher Bunka |
3/4/5
Director
|
—
mixed-class rows
|
$533,006
740,289 shares
mixed-class rows
|
— | 17 Mar 2026 |
| Richard Christopher |
3/4/5
Chief Executive Officer, Director
|
—
mixed-class rows
|
$363,611
415,000 shares
mixed-class rows
|
— | 29 Jul 2025 |
| John Martin Docherty |
3/4/5
President & CSO, Director
|
—
mixed-class rows
|
$322,458
370,285 shares
mixed-class rows
|
— | 29 Jul 2025 |
| Invenomic Capital Management LP |
13F
Company
|
—
class O/S missing
|
$290,555
470,915 shares
|
— | 31 Dec 2025 |
| UBS Group AG |
13F
Company
|
—
class O/S missing
|
$222,923
361,300 shares
|
— | 31 Dec 2025 |
| VANGUARD GROUP INC |
13F
Company
|
—
class O/S missing
|
$159,689
258,816 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
28
Shares
1,490,596
Rows available
28
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
21
Q1 2026 holders
28
Holder diff
7
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend